Why Chemours stock is on investors’ radar

Chemours (CC) has drawn fresh attention after its first quarter 2026 earnings, where several business segments outperformed expectations, and management highlighted debt reduction, refinancing activity, and reaffirmed full year sales and EBITDA guidance.

That interest has come against a sharp pullback in recent days, with a 1 day share price return of 5.32% decline and a 7 day share price return of 16.85% decline, even though the 90 day share price return of 22.33% and 1 year total shareholder return of 104.63% still point to strong momentum compared with the longer term 3 year and 5 year total shareholder returns, which remain negative.

If Chemours has you rethinking where growth or income could come from next, it can be useful to scan other materials-linked ideas using our curated list of 8 top copper producer stocks

With Chemours stock still up strongly over 1 year but down sharply over the past week, combined with a value score of 5 and an estimated intrinsic discount of 64%, is there genuine upside left here, or is the market already pricing in future growth?

Most Popular Narrative: 37.2% Overvalued

At a last close of $22.41 against a narrative fair value of $16.33, Chemours is framed as richly priced, with the story hinging on a sharp profit swing and higher future earnings multiples.

Analysts expect earnings to reach $671.0 million (and earnings per share of $2.18) by about September 2028, up from $-412.0 million today.

In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 4.6x on those 2028 earnings, up from -6.1x today.

Want to understand why a loss making business is assigned a higher future earnings multiple and still lands below today’s price? The narrative leans on moderate revenue growth, a strong shift in margins, and a compressed valuation multiple that has to do a lot of heavy lifting. The details of those projections, and how they interact with the discount rate, are where this fair value really takes shape.

Result: Fair Value of $16.33 (OVERVALUED)

However, legal and regulatory pressure around PFAS, along with potential demand and pricing pressure in Titanium Technologies, could quickly challenge the profit and valuation assumptions behind this story.

Another Angle On Value

While the fair value narrative pegs Chemours at $16.33 and calls the stock overvalued at $22.41, the SWS DCF model points a very different way, with a future cash flow value of $62.68. When cash flow math disagrees this much with earnings based stories, which signal do you trust more?

Next Steps

If this mix of risks and potential rewards feels finely balanced, do not wait on others to tell you how to feel. Instead, weigh both sides for yourself by checking the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Chemours is on your radar, do not stop there. Broadening your watchlist with other focused ideas can highlight opportunities you might otherwise miss.

• Target potential mispricings by scanning a curated set of 51 high quality undervalued stocks that pair quality fundamentals with compressed valuations.
• Strengthen your income stream by reviewing 12 dividend fortresses built around higher yielding companies with resilient payout histories.
• Protect the downside of your portfolio by checking 71 resilient stocks with low risk scores designed to spotlight companies with lower overall risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.